HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice.

AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1263-9. Unique Identifier : AIDSLINE MED/98435939
Scott DE; Golding H; Huang LY; Inman J; Golding B; Laboratory of Plasma Derivatives, Division of Hematology, Center; for Biologics Evaluation and Research, U.S. Food and Drug; Administration, Bethesda, Maryland 20892, USA.

Abstract: Enhancement of immunity in the setting of HIV infection is difficult owing to loss of functional CD4+ T cells. The MHC class II-deficient mouse (II-/-) environment simulates that of the immunocompromised HIV-infected individual, since these mice have low CD4+ T cell numbers, defective CD4-dependent responses, and are susceptible to opportunistic infection. This strain was used to test whether heat-killed Brucella abortus (BA), covalently conjugated to the V3 peptide of HIV-1 (MN), could elicit anti-HIV responses. V3-BA, but not the T-dependent antigen V3-KLH, induced high levels of IL-12, IFN-gamma, and IL-10 mRNA in both wild-type (WT) and II-/- mice within 24 hr of injection. V3-BA-treated, but not V3-KLH-treated, II-/- mice developed serum IgG and IgA anti-V3 antibodies, with IgG2b and IgG3 as the predominant isotype. Viral neutralization studies, using a syncytium inhibition assay, demonstrated that the antibodies generated by V3-BA in II-/- mice were capable of neutralizing HIV. These experiments demonstrate that a heat-inactivated bacterium such as BA, when used as a carrier, can generate a cytokine environment that results in the production of neutralizing antiviral antibodies in an immunodeficient host. Such strategies could be important in the development of immunotherapies and vaccines for HIV-1 patients.

Keywords: JOURNAL ARTICLE Animal AIDS Vaccines/ADMINISTRATION & DOSAGE/*IMMUNOLOGY Brucella abortus/*IMMUNOLOGY Cytokines/*METABOLISM CD4-Positive T-Lymphocytes/IMMUNOLOGY Disease Models, Animal Heat HIV Antibodies/*BLOOD HIV Envelope Protein gp120/*IMMUNOLOGY HIV-1/*IMMUNOLOGY IgA/BLOOD IgG/BLOOD Immunoglobulin Isotypes Immunologic Deficiency Syndromes/*IMMUNOLOGY Mice Mice, Inbred C57BL Neutralization Tests Peptide Fragments/*IMMUNOLOGY RNA, Messenger/METABOLISM Support, U.S. Gov't, P.H.S. Vaccines, Conjugate/ADMINISTRATION & DOSAGE/*IMMUNOLOGY
990228
A9920907

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .